Literature DB >> 34016285

Mucormycosis.

Julie M Steinbrink1, Marisa H Miceli2.   

Abstract

Mucormycosis is a rare but aggressive fungal disease that mainly affects patients with poorly controlled diabetes mellitus and those who are severely immunocompromised, including patients with hematological malignancies and solid organ transplant recipients. Early recognition of infection is critical for treatment success, followed by prompt initiation of antifungal therapy with lipid formulation amphotericin B. Posaconazole and isavuconazole should be used for stepdown and salvage therapy. Surgical debridement is key for tissue diagnosis and treatment and should be pursued urgently whenever possible. In addition to surgery and antifungal therapy, reverting the underlying risk factor for infection is important for treatment response.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Immunocompromised host; Mucorales; Mucormycosis

Mesh:

Substances:

Year:  2021        PMID: 34016285     DOI: 10.1016/j.idc.2021.03.009

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  8 in total

Review 1.  Clinical Manifestations of Pulmonary Mucormycosis in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A 21-Case Series Report and Literature Review.

Authors:  Jing Bao; Chunyu Liu; Yongxia Dong; Yu Xu; Zhanwei Wang; Kunkun Sun; Wen Xi; Keqiang Wang; Pihua Gong; Zhancheng Gao
Journal:  Can Respir J       Date:  2022-06-02       Impact factor: 2.130

2.  Oral Tissue Involvement and Probable Factors in Post-COVID-19 Mucormycosis Patients: A Cross-Sectional Study.

Authors:  Neelam Chandwani; Sandeep Dabhekar; Kalai Selvi; Roshan Noor Mohamed; Shahabe Saquib Abullais; Muhamood Moothedath; Ganesh Jadhav; Jaya Chandwani; Mohmed Isaqali Karobari; Ajinkya M Pawar
Journal:  Healthcare (Basel)       Date:  2022-05-13

Review 3.  COVID-19 associated mucormycosis - An emerging threat.

Authors:  Chien-Ming Chao; Chih-Cheng Lai; Wen-Liang Yu
Journal:  J Microbiol Immunol Infect       Date:  2022-01-13       Impact factor: 10.273

Review 4.  COVID-19 and metabolic disease: mechanisms and clinical management.

Authors:  Charlotte Steenblock; Peter E H Schwarz; Barbara Ludwig; Andreas Linkermann; Paul Zimmet; Konstantin Kulebyakin; Vsevolod A Tkachuk; Alexander G Markov; Hendrik Lehnert; Martin Hrabě de Angelis; Hannes Rietzsch; Roman N Rodionov; Kamlesh Khunti; David Hopkins; Andreas L Birkenfeld; Bernhard Boehm; Richard I G Holt; Jay S Skyler; J Hans DeVries; Eric Renard; Robert H Eckel; K George M M Alberti; Bruno Geloneze; Juliana C Chan; Jean Claude Mbanya; Henry C Onyegbutulem; Ambady Ramachandran; Abdul Basit; Mohamed Hassanein; Gavin Bewick; Giatgen A Spinas; Felix Beuschlein; Rüdiger Landgraf; Francesco Rubino; Geltrude Mingrone; Stefan R Bornstein
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-04       Impact factor: 32.069

Review 5.  COVID19 associated mucormycosis: A review.

Authors:  Priyadharsini R Palanisamy; Dhivya Elango
Journal:  J Family Med Prim Care       Date:  2022-02-16

6.  Severe Adaptive Immune Suppression May Be Why Patients With Severe COVID-19 Cannot Be Discharged From the ICU Even After Negative Viral Tests.

Authors:  Yue Zhou; Xuelian Liao; Xiangrong Song; Min He; Fei Xiao; Xiaodong Jin; Xiaoqi Xie; Zhongwei Zhang; Bo Wang; Chenliang Zhou; Yan Kang; Wei Zhang
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

Review 7.  Mycotic infection as a risk factor for COVID-19: A meta-analysis.

Authors:  Anlin Liu; Zhengtu Li; Guansheng Su; Ya Li; Yuzhuo Zhang; Jinkai Liang; Xiaoxue Cheng; Xidong Wang; Yongming Li; Feng Ye
Journal:  Front Public Health       Date:  2022-09-07

8.  Mucormycosis in the Urinary Bladder-the Devil Is in the Details.

Authors:  Manjeet Kumar; Pawan Kaundal; Sunish Sharma; Kirti Rana
Journal:  Indian J Surg       Date:  2022-08-31       Impact factor: 0.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.